• Late-Breaking Posters – Late-breaking science included in the poster session.
• Poster Presentation – Poster board presentation in a general session.
• Individual Research Report – Selected by the Program Committee, these are 10 minute oral presentation with 5 minutes Q&A from the audience.
• (CLOSED) Panel Sessions – Have a Chair, a minimum of 3 Speakers but no more than 4 speakers, and a discussant. A co-chair is optional. Panel sessions are 1.5 hours in length. 
• (CLOSED) Workshop Sessions – Integrative session with a chair and no more than 8 participants. A discussant and co-chair is optional. Workshop sessions are 2 hours in length.
• Pharmaceutical Pipeline Presentations– A Pharmaceutical Pipeline report will be a 10 minute presentation and will also have the opportunity to present their research as a poster presentation. A Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on any CNS compound for which Phase 3 data has not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest.

The 2023 ASCP Annual Meeting is the premier meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies, and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Program Committee for the Annual Meeting chaired by Drs. Susan Kornstein and Mark Rapaport including representatives from the ASCP Community, FDA, EMA, NIMH, NIDA, NIAAA, and the academia members, lead the direction of the meeting. The Review Subcommittee, under the leadership of Drs. Lee Cohen and Manish Jha, are responsible for the review of all program submissions. To ensure the meeting includes the needs of our loyal pharmaceutical industry members, we are excited to announce the launch of the ASCP Industry Advisory Council led by Dr. Ross Baker.

The ASCP Annual Meeting brings together over 1200 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator awardees.  ASCP is joined by federal partners, the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism, (NIAAA) and the Food and Drug Administration (FDA) to organize a program that emphasizes the presentation of information that has not been previously published or presented. For more information about the history and purpose of the ASCP Annual Meeting please click here.

In recent years, the ASCP Annual Meeting focus has been expanded to address a number of timely issues relevant to clinical research in psychiatry, including the translation of research into practice, the importance of regulatory issues, and pharmacogenetics and other means to personalizing interventions.

Embargo and Media Policy: Any press release issued by a presenter, the presenter's employer, or any other outside person or entity about a presentation scheduled for the ASCP Annual Meeting must be reviewed by the ASCP Officers and should be clear that it is not sanctioned by ASCP. Press releases do not need to be embargoed. All media personnel requesting waived access to ASCP meetings must provide a letter of request on company letterhead. Media requests will be reviewed and approved by the ASCP Officers.